Abstract: Objective To investigate the efficacy and safety of combined therapy of telbivudine and compound embryonic bovine liver extract in patients with chronic hepatitis B（CHB）. Methods Eighty-seven patients with chronic hepatitis B were randomly divided into combination treatment group （n=43） and control group（n=44）. Patients in combination treatment group were treated with compound embryonic bovine liver extract plus telbivudine,and those in control group were treated with telbivudine alone. The data of liver function index,renal function index,serum hyaluronic acid （HA）,laminin （LN）,type IV collagen（IV-C）,type III procollagen,N-terminal peptide（P IIINP）,creatine kinase（CK）,HBV DNA undetectable rates,HBeAg loss rates and adverse reaction rates were compared between the two groups. Results At the end of 24 weeks of treatment,serum alanine transaminase （ALT）,aspartate aminotransferase （AST） levels in combination treatment group were（25.4±8.5） U/L,（23.8±6.5） U/L,respectively,significantly lower than those in control group [（46.3±9.3） U/L,（49.0±7.3）U/L,P<0.05];serum HA,LN,Ⅳ-C,PⅢNP levels in combination treatment group were（128.4±83.2） μg/L,（88.4±64.3） μg/L,（64.4±49.0） μg/L,（112.3±73.8） μg/L,respectively,significantly lower than those in control group[（249.3±82.1） μg/L,（163.1±55.1） μg/L,（98.2±50.3） μg/L,（183.2±63.2） μg/L,P<0.01];serum HBV DNA undetectable,HBeAg loss and adverse reaction rates in the two groups were not significantly different（P>0.05）. Conclusions Telbivudine combined with compound embryonic bovine liver extract can significantly improve the liver function and liver fibrosis in patients with CHB,and have a good safety profile.

Key words: Chronic hepatitis B, Telbivudine, Compound embryonic bovine liver extract, Therapy